retatrutide trial results 2025 news Lilly's triple agonist achieves 16.8% weight loss in phase 3 This is exciting. 👀 The

Research news Mouse experiments have suggested that glucagon-like peptide-1 receptor agonists may reduce pulmonary fibrosis following a COVID-19 infection in people with type 2 diabetes, although researchers cautioned that the findings remain preliminary Glucagon-like peptide-1 (GLP-1) receptor agonists, already used to treat type 2 diabetes (T2DM) and obesity, may also help to reduce the risk of COVID-19-related lung scarring in people with T2DM, according to research in mouse models

The CCN credential matters here

Shortening below 4 weeks consistently increases adverse event rates without improving outcomes

Molecular analysis of CD26 mediated signal transduction in T cells

Protein-forward and nutrient-dense innovations belong at the center of every pipeline

Increased Gram-negative Enterobacteriaceae and decreased acetic acid-producing bacteria (such as Bifidobacteria ) associated with T2D resulted in increased LPS release and decreased acetic acid, respectively